Immunotherapy-chemotherapy combo boosts survival for patients with metastatic colorectal cancer

FHS
May 24, 2024
4:39 pm

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.

CRT-D Upgrade Suits Patients With Pacing-Related Heart Failure

AMSTERDAM — A cardiac resynchronization therapy (CRT) upgrade produced solid clinical benefit for patients with pacing-induced heart failure with reduced ejection fraction (HFrEF), the small

August 28, 2023

Simple biomarkers offer early warning of hidden heart risk in childhood cancer survivors

Data from the St. Jude lifetime cohort study (St. Jude LIFE) revealed that two common biomarkers of cardiac function and damage could better predict cardiomyopathy within five

January 12, 2024

Acalabrutinib maleate by AstraZeneca for Marginal Zone B-cell Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.